Skip to main content
Erschienen in: Endocrine 2/2020

28.04.2020 | COVID-19 | Letter to the Editor Zur Zeit gratis

COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications

verfasst von: Rimesh Pal

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Excerpt

A novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over 1,000,000 individuals, claiming more than 56,000 lives in over 200 countries worldwide ever since its mysterious outbreak in Wuhan, China in December 2019. The largest case series from China had shown that majority of the patients belonged to the age group of 30–79 years. Most of the cases were mild (81%), while 14% cases were severe and only 5% critical. The overall case-fatality rate was 2.3% [1]. SARS-CoV-2 primarily affects the lungs, resulting in viral pneumonia often complicated by acute respiratory distress syndrome and sepsis. The virus is able to evade the host immune system by avoiding detection of their dsRNA and by inhibiting the host interferon-I pathway [2]. The pathogen enters the pneumocyte using the host angiotensin-converting enzyme 2 (ACE2) as a receptor. In addition, the enzyme is expressed on the arterial and venous endothelial cells of many organs including the adrenal glands. Autopsy studies on patients who died from SARS (the original outbreak in 2003) had shown degeneration and necrosis of the adrenal cortical cells. The SARS-CoV (the ‘cousin’ of SARS-CoV-2) was in fact identified in the adrenal glands, hinting towards a direct cytopathic effect of the virus. Hence it is likely that cortisol dynamics may be altered in patients with SARS (and COVID-19). However, the literature is scarce is this regard. …
Literatur
3.
Zurück zum Zitat R. Wheatland, Molecular mimicry of ACTH in SARS—implications for corticosteroid treatment and prophylaxis. Med. Hypoth. 63, 855–862 (2004)CrossRef R. Wheatland, Molecular mimicry of ACTH in SARS—implications for corticosteroid treatment and prophylaxis. Med. Hypoth. 63, 855–862 (2004)CrossRef
4.
Zurück zum Zitat M.K.-S. Leow, D.S.-K. Kwek, A.W.-K. Ng, K.-C. Ong, G.J.-L. Kaw, L.S.-U. Lee, Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin. Endocrinol. (Oxf.) 63, 197–202 (2005)CrossRef M.K.-S. Leow, D.S.-K. Kwek, A.W.-K. Ng, K.-C. Ong, G.J.-L. Kaw, L.S.-U. Lee, Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin. Endocrinol. (Oxf.) 63, 197–202 (2005)CrossRef
5.
Zurück zum Zitat C.D. Russell, J.E. Millar, J.K. Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020)CrossRef C.D. Russell, J.E. Millar, J.K. Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020)CrossRef
Metadaten
Titel
COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications
verfasst von
Rimesh Pal
Publikationsdatum
28.04.2020
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02325-1

Weitere Artikel der Ausgabe 2/2020

Endocrine 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.